Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16936038 | 0.87 | KLK7 (0.77) | KLK7MAPTALDH1A1THRBMEN1 | |
| SCHEMBL22475217 | 0.86 | KLK7 (0.79) | KLK7MAPTALDH1A1THRBMEN1 | |
| SCHEMBL18354574 | 0.85 | KLK7 (1.00) | KLK7MAPTALDH1A1THRBMEN1 | |
| SCHEMBL16946209 | 0.85 | KLK7 (1.00) | KLK7MAPTALDH1A1THRBMEN1 | |
| SCHEMBL19272546 | 0.79 | KLK7 (0.77) | KLK7ALDH1A1TDP1EPHX2 | |
| SCHEMBL12931990 | 0.78 | EPHX2 (1.00) | KLK7MAPTALDH1A1MEN1LMNA | |
| SCHEMBL16936037 | 0.77 | KLK7 (1.00) | KLK7MAPTALDH1A1KMT2ATDP1 | |
| SCHEMBL18354572 | 0.75 | KLK7 (1.00) | KLK7ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL18354489 | 0.75 | KLK7 (1.00) | KLK7MAPTALDH1A1MEN1LMNA | |
| SCHEMBL16936096 | 0.72 | KLK7 (0.76) | KLK7MAPTALDH1A1THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744148-B2 | Kallikrein 7 inhibitors | SIXERA PHARMA AB (SE) | 2017-08-29 | — | — | US | disclosed |
| US-9744148-B2 | Kallikrein 7 inhibitors | SIXERA PHARMA AB (SE) | 2017-08-29 | — | — | US | disclosed |
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
| WO-2015112079-A1 | NEW KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | KLK7, KLK5, KLK1 | KLK7 1/4885MAPT 1927/4885ALDH1A1 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.